Videregen is a leader in the development of personalised, regenerative products to replace, repair and restore organs and tissues. They are a clinical-stage regenerative medicine company using our proprietary technology platform to develop a range of personalised regenerative products targeting chronic, serious and orphan indications.
Targeting the growing need for regenerative therapies for serious and life-threatening diseases, Videregen’s leading programmes are focused on the development of a portfolio of medicinal products with a lead indication targeting life-threatening complications following lung surgery.
The Company’s patented technology and know-how are also being applied to the development of other regenerative organ and tissue replacement products; including airways, gastrointestinal, and immunological indications.
Find out more about Videregen on their website.
